ISHAS COVID-19/HYALURONAN FORUM

ISHAS Professional & Academic Forum on Targeting Hyaluronan/Hyaluronic Acid (HA) in COVID-19 Infection and Pathology. (You do not need to be a Member of ISHAS to post on this forum.)
  1. Anthony Day
  2. Therapeutics Targeting Hyaluronan after COVID-19 Infection
  3. Friday, 08 May 2020
I received this yesterday - a CRO offering an IPF model to test therapeutics on lung fibrosis, which could be relevant as treatments will be needed post COVID-19 infection or due to time spent on ventilators (see Eva Turley's comment in the pdf summary in introduction to the forum).
Tony

I’m writing to you today with an update regarding the relationship between lung fibrosis and COVID-19.
I hope you and your team are healthy and safe amid the current pandemic.

Currently, there is an urgent need to develop diagnostic and therapeutic methods to curb the global spread of COVID-19.
It has been suggested that COVID-19 may cause not only pneumonia, but also cause damage to other organs such as the liver, kidney and intestines. Recent reports have focused on lung fibrosis.

COVID-19 is a virus belonging to the beta-coronavirus class, similar to the virus that causes severe acute respiratory syndrome (SARS). It has been reported that fibrosis could begin to be observed several weeks after infection during the SARS epidemic. In subsequent follow-up studies, more than 20% of SARS survivors at one year later had pulmonary fibrosis, indicating that pulmonary fibrosis is a long-term problem [David S. Hui et al., Chest., 2005; Lixin Xie et al., Respir Res., 2005]. In COVID-19 patients, it was reported that fibrosis symptoms were observed in the analysis using CT, and it is speculated that the issue of fibrosis will emerge in the future [Zheng Ye., European Radiology, 2020].

At SMC, we offer an Idiopathic pulmonary fibrosis (IPF) model as a fibrosis model of the lung, with which we have a lots of testing experience.
Since it has been reported that IPF is caused by lung damage due to viral infection, it is speculated that the demand for the development of lung fibrosis therapies will increase after the COVID-19 epidemic subsides.
If you are researching the prevention and treatment of fibrosis by COVID-19, please consider our IPF model.

Although we are taking precautionary measures for the safety of our staff, we at SMC are committed to continue providing CRO services to address current challenges and contribute to the development of life saving medicines.
We have a variety of fibrotic and inflammatory disease models as well as the IPF model, and provide drug efficacy evaluation testing services.
For more information, please get in touch.

Kind regards,
Mio

******************************************************************
Mio Arakawa
SMC Laboratories, Inc.
2-16-1 Minami-Kamata Ota-City Tokyo 144-0035 Japan
TEL: +81-3-6715-9101 FAX: +81-3-6715-9120
E-mail: arakawa@smclab.co.jp URL: https://smccro-lab.com/
******************************************************************
Comment
There are no comments made yet.
Stavros Garantziotis
Forum Subscriber
Accepted Answer Pending Moderation
0
Votes
Undo
This is very interesting. Frankly, i would like some more detail. There is no IPF model in the mouse, as far as i know. There are several fibrosis models, but they only recapitulate parts of the human IPF. They are also all reversible, as opposed to human IPF. It would be interesting to know what model they are using
Comment
  1. Anthony Day
  2. 1 month ago
  3. #16
Stavros, could you perhaps contact the company (SMC Laboratories Inc) to find out and then post your findings here? I included the contact details for the company in my post above. ;-)

That would be really helpful and I am sure those working on IPF ,and lung fibrosis in general, would appreciate this.
There are no comments made yet.
  • Page :
  • 1


There are no replies made for this post yet.
Be one of the first to reply to this post!

HA FORUM - Welcome

Log in

Register